SRC‐3 has been shown to promote HCC cell proliferation through activation of the AKT signaling pathway to regulate cycle control‐related gene such as inhibit cell cycle inhibitor p21Cip1/Waf1 expression, whereas PI3K/AKT inhibitor LY294002 can abolish the effect of SRC‐3 13. This evidence concerns the gene CDKN1A and hepatocellular carcinoma.